2Pan XR, Yang WY, Li GW. National diabetes prevention and control factors in China, 1994. National Diabetes Prevention and Control Cooperative group. Diabetes Care, 1997,20 : 1664 - 1669.
4Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol, 2000, 90:3 ~ 10.
5National Cholesterol Education Program.( NCEP ) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults ( Adult treatment Panel Ⅲ ) Third report of the national cholesterol education program. Circulation, 2002, 106 : 3143 3421.
6Lindstrom J, Cauherantu A, Maunelin M. The finish diabetes prevention study (PPS). Lifestyle in- tervention and 3 -years results on diet and physical activity. Diabetes Care ,2003,26:3236.
7Korytkowski M, Thomas A, Reid L, et al. Gemepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care, 2002,252 : 1607 - 1611.
8The STOP-NIDDM trial. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA,2003,290:486 - 494.
9Gerstein HC, Yulsuf S, Bosch J, et al. DREAM (Diabetic Reduction Assessment with Ramipril and Rosiglitazone Medication) trial investigators, effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet ,2006,368 : 1096 - 1105.
10American Diabetes Association. standards of medical care in diabetes 2007. Diabetes Care, 2007, 30:4 -41.
3National Diabetes Data Group. Diabetes in America. 2nd ed, USA: NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 1995. NIH Publication No. 95-1468.
4Dowse GK, Zimmet P. A model for a diabetes and other non-communicable disease survey. World Health Statistics Quarterly, 1992,5:360.
5King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care, 1998,21:1414-1431.
